Proteomics

Dataset Information

0

Plasma Proteomics Analysis of a Transglutaminase 2 inhibitor in Celiac Disease


ABSTRACT: Individuals with celiac disease (CeD) on a long-term gluten-free diet (GFD) underwent a 6-week gluten challenge combined with 100mg per day of the transglutaminase 2 enzyme -inhibitor, ZED1227 (PGCd, n = 28) or placebo (PGCp, n = 19). The samples were collected at baseline (GFD) and post-gluten challenge (PGC). Mass spectrometry-based lipidomic and proteomics profiling, along with genome-wide DNA methylation analysis, were applied to plasma samples obtained from 47 CeD patients. Comparative analyses were performed between the groups, with adjustment for BMI, age, sex, and country of origin.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Celiac Disease

SUBMITTER: Robert Moulder  

LAB HEAD: Professor Riitta Lahesmaa

PROVIDER: PXD069597 | Pride | 2026-06-15

REPOSITORIES: Pride

Dataset's files

Source:
altmetric image

Publications


BACKGROUND: Celiac disease (CeD) is an autoimmune disease triggered by dietary gluten in genetically predisposed individuals. Deamidation of gluten peptides by the CeD autoantigen and enzyme transglutaminase 2 (TG2) is central to the pathogenesis of CeD. Inhibition of TG2 with the specific inhibitor ZED1227 effectively prevents gluten-induced histological damage in CeD patients. Here we aimed to explore the systemic plasma lipidomic, proteomic and DNA methylomic changes in ZED1227-treated CeD pa  ...[more]

Publication: 1/2

Similar Datasets

2025-04-08 | PXD050655 | Pride
2026-06-18 | GSE319777 | GEO
2019-02-01 | GSE125983 | GEO
2024-07-12 | GSE200075 | GEO
2026-04-01 | PXD059719 | Pride
2024-03-15 | PXD045913 | Pride
2026-05-31 | GSE333246 | GEO
2026-03-04 | GSE298129 | GEO
2025-08-06 | GSE273155 | GEO
2019-07-26 | GSE134900 | GEO